Peter Blume-Jensen - 21 Feb 2026 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
President and CEO, Director
Signature
/s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen
Issuer symbol
ACRV
Transactions as of
21 Feb 2026
Net transactions value
-$21,825
Form type
4
Filing time
24 Feb 2026, 16:12:46 UTC
Previous filing
18 Feb 2026
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (2)

Name Relationship Address Signature Signature date CIK
Blume-Jensen Peter President and CEO, Director C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN /s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen 24 Feb 2026 0001950499
Masson Kristina EVP - Business Operations, Director C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN /s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson 24 Feb 2026 0001950501

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Tax liability $21,825 -14,265 -0.68% $1.53 2,080,204 21 Feb 2026 Direct F1, F2
holding ACRV Common Stock 314,127 21 Feb 2026 See Footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
F2 These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
F3 These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.